Investors of RxSight, Inc. notified of upcoming Securities Fraud Class Action lawsuit; BFA Law invites those who suffered losses (NASDAQ: RXST) to reach out.

In early 2024, RxSight, a company that manufactures and sells light adjustable intraocular lenses used in cataract surgery and related capital equipment, was sued by Bleichmar Fonti & Auld LLP (BFA) for alleged securities fraud related to misrepresentations made to investors.

The lawsuit, filed in the U.S. District Court for the Central District of California, under the caption Makaveev v. RxSight, Inc., et al., No. 25-cv- 01596, asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. During the relevant period, RxSight failed to disclose "adoption challenges" in its products, according to the lawsuit.

Bleichmar Fonti & Auld LLP, a leading international law firm representing plaintiffs in securities class actions and shareholder litigation, is spearheading the class-action lawsuit. The firm's attorneys have been named "Elite Trial Lawyers" by the National Law Journal, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360, and "SuperLawyers" by Thomson Reuters.

All representation in the RxSight class-action lawsuit is on a contingency fee basis, meaning shareholders in the lawsuit will not be responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses in the lawsuit.

In April and July 2025, RxSight cut its 2025 full-year revenue forecast, causing the price of its stock to decline roughly 38%. The company's main product is its Light Adjustable Lens (LAL) that can be customized after cataract surgery through a series of non-invasive light treatments.

Investors who purchased RxSight securities may have until September 22, 2025, to ask the Court to be appointed to lead the case. For more information about the lawsuit or to contact Ross Shikowitz at Bleichmar Fonti & Auld LLP, visit https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit or email [email protected] or call 212.789.3619.

It's worth noting that BFA has a track record of significant recoveries. The firm recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. To learn more about BFA and its attorneys, visit https://www.bfalaw.com.

Investors of RxSight, Inc. notified of upcoming Securities Fraud Class Action lawsuit; BFA Law invites those who suffered losses (NASDAQ: RXST) to reach out.